Topiramate and Cognitive Function in Migraine

J Gordon Millichap

doi:10.15844/pedneurbriefs-24-3-8

Topiramate and Cognitive Function in Migraine

Pediatric Neurology Briefs

Volume 24 (2010): Issue 3

By: J Gordon Millichap

Open Access

|Mar 2010

Abstract

Researchers at the Johnson & Johnson Pharmaceutical Research & Development, New Jersey and Belgium, and University of California, Los Angeles, CA used the Cambridge Neuropsychological Test Automated Battery (CANTAB) and cognitive adverse events to evaluate neurocognitive effects of topiramate 100 mg/day vs placebo in 70 migraine patients aged 12 through 17 years.

References

Pandina GJ Ness S Polverejan E Yuen E Eerdekens M Bilder RM Cognitive effects of topiramate in migraine patients aged 12 through 17 years Pediatr Neurol 2010 Mar 42 3 187 195 10.1016/j.pediatrneurol.2009.10.001 20159428
Open DOI Search in Google Scholar Back to article
Hershey AD Powers SW Vockell AL LeCates S Kabbouche M Effectiveness of topiramate in the prevention of childhood headaches Headache 2002 Sep 42 8 810 818 12390646
Search in Google Scholar Back to article
Ferraro D Di Trapani G Topiramate in the prevention of pediatric migraine: literature review J Headache Pain 2008 Jun 9 3 147 150 10.1007/s10194-008-0030-1 18385933
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-24-3-8 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 23 - 23

Published on: Mar 1, 2010

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Cambridge Neuropsychological Test Automated Battery,

Word Fluency,

Dizziness

© 2010 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 24 (2010): Issue 3